Edition:
India

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,023.00GBp
12 Dec 2017
Change (% chg)

-5.00 (-0.49%)
Prev Close
1,028.00
Open
1,032.00
Day's High
1,039.00
Day's Low
1,021.00
Volume
57,521
Avg. Vol
1,182,088
52-wk High
2,346.00
52-wk Low
906.50

Latest Key Developments (Source: Significant Developments)

Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - HIKMA PHARMACEUTICALS PLC ::‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​.FOR FULL YEAR ‍CONTINUE TO EXPECT GLOBAL INJECTABLES REVENUE TO BE AROUND $775 MILLION, WITH A VERY STRONG CORE OPERATING MARGIN OF AROUND 39%​.‍EXPECT GENERICS REVENUE TO BE AROUND $600 MILLION FOR FULL YEAR AND CORE OPERATING MARGIN TO BE IN LOW SINGLE-DIGITS​.‍REITERATING EXPECTATION FOR BRANDED REVENUE GROWTH IN MID-SINGLE DIGITS IN CONSTANT CURRENCY IN 2017​.  Full Article

Hikma signs licensing deal with Orion for asthma product
Monday, 13 Feb 2017 

Hikma Pharmaceuticals Plc : Licensing agreement with orion for EASYHALER . Signed an exclusive licensing and distribution agreement with Orion Corporation Of Finland, for its new Easyhaler combination product .Under terms of agreement, Hikma has exclusive rights to register, distribute, market and sell product in all of its MENA markets.  Full Article

Hikma says first-half revenue up 28 pct
Wednesday, 24 Aug 2016 

Hikma Pharmaceuticals Plc : Interim dividend $0.11 per share . H1 revenue $882 mln up 28 pct . H1 operating profit $121 mln down 27 pot . H1 group core operating profit of $176 mln, down 14 pct and down 3 pct in constant currency . Interim dividend of 11.0 cents per share, in line with interim dividend for H1 2015 . Continue to expect 2016 group revenue in range of $2.0 bln to $2.1 bln in constant currency, driven by strong growth in injectables and branded . Remain on track to achieve revenue growth and cost synergy targets that we have set ourselves for West-Ward Columbus in 2017 . H1 global injectables revenue of $357 mln, up 4 pct from H1 2015 and up 5 pct in constant currency . H1 generics revenue of $257 mln, compared with $79 mln in H1 2015, primarily reflecting consolidation of four months of revenue from West-Ward Columbus . H1 generics core operating profit of $8 mln, with a core operating margin of 3.1 pct, reflecting product mix and high operating costs . Continue to expect full year generics revenue in range of $640 mln to $670 mln in 2016, including ten months of West-Ward Columbus . Continue to expect core generics operating profit in range of $30 mln to $40 mln in 2016 . H1 branded revenue of $264 mln, down 6 pct and up 1 pct in constant currency . H1 branded core operating profit of $55 mln, down 5 pct and up 28 pct in constant currency.  Full Article

Basilea Pharmaceutica: distribution agreement with Hikma for Cresemba in MENA region
Wednesday, 17 Aug 2016 

Basilea Pharmaceutica AG :Basilea announces distribution agreement with Hikma for Cresemba (isavuconazole) in the MENA region.  Full Article

Hikma sees FY revenue between $2-$2.1 bln
Wednesday, 3 Aug 2016 

Hikma Pharmaceuticals Plc : Trading statement . Performed well in first half of 2016 . Continue to expect group revenue to be in range of $2.0 bln to $2.1 bln for full year . Expect West-Ward Columbus revenue to increase to between $700 mln to $750 mln in 2017 as new product launches accelerate . For full year, we continue to expect revenue for combined generics business to be in range of $640 mln to $670 mln .Expect to achieve cost savings in range of $35 mln to $45 mln by end of 2017.  Full Article

Hikma says U.S. Court of Appeals upholds regulatory approval of colchicine
Thursday, 21 Jul 2016 

Hikma Pharmaceuticals Plc : Fda's regulatory approval of hikma's colchicine 0.6 mg capsule product was upheld. . May continue marketing colchicine 0.6 mg capsules under brand name mitigare™, as well as its authorised generic . Regulatory approval of hikma's colchicine upheld .Us court of appeals affirmed earlier decision of us district court for columbia finding in favour of us fda and hikma.  Full Article

Hikma Pharma reiterates guidance for 2016
Thursday, 12 May 2016 

Hikma Pharmaceuticals Plc : Hikma reiterates guidance for 2016 . Continue to expect full year group revenue to be in range of $2.0 billion to $2.1 billion . Remain on track to deliver global injectables revenue growth in mid to high-single digits in 2016 . Continue to expect injectables core operating margin to return to a more normalised level of around 36 pct . We expect branded revenue to be stronger in second half .Continue to expect 2016 revenue for combined generics to be in range of $640 million to $670 million.  Full Article

BRIEF-Hikma Says Hikma Ventures Has Participated In Financing For Prognos​

* ‍VENTURE CAPITAL ARM, HIKMA VENTURES HAS PARTICIPATED IN A $20.5 MILLION SERIES C ROUND OF FINANCING FOR PROGNOS​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)